UBS AM’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $85M | Sell |
504,233
-67,486
| -12% | -$10M | 0.02% | 542 |
|
|
2026
Q1 | $75.3M | Sell |
571,719
-150,757
| -21% | -$20M | 0.02% | 553 |
|
|
2025
Q4 | $102M | Sell |
722,476
-42,761
| -6% | -$6.19M | 0.02% | 488 |
|
|
2025
Q3 | $107M | Sell |
765,237
-622,398
| -45% | -$84.3M | 0.02% | 465 |
|
|
2025
Q2 | $174M | Buy |
1,387,635
+228,268
| +20% | +$26.2M | 0.04% | 414 |
|
|
2025
Q1 | $128M | Buy |
1,159,367
+89,271
| +8% | +$11.3M | 0.03% | 479 |
|
|
2024
Q4 | $146M | Buy |
1,070,096
+175,879
| +20% | +$21.8M | 0.03% | 438 |
|
|
2024
Q3 | $103M | Sell |
894,217
-17,847
| -2% | -$2.45M | 0.03% | 516 |
|
|
2024
Q2 | $126M | Buy |
912,064
+312,640
| +52% | +$42.9M | 0.04% | 407 |
|
|
2024
Q1 | $82.7M | Sell |
599,424
-18,029
| -3% | -$2.46M | 0.03% | 486 |
|
|
2023
Q4 | $81.4M | Buy |
617,453
+28,162
| +5% | +$3.24M | 0.03% | 480 |
|
|
2023
Q3 | $66.3M | Buy |
589,291
+20,413
| +4% | +$2.15M | 0.03% | 504 |
|
|
2023
Q2 | $57.6M | Hold |
568,878
| – | – | 0.03% | 520 |
|
|
2023
Q1 | $57.6M | Buy |
568,878
+26,266
| +5% | +$2.73M | 0.03% | 520 |
|
|
2022
Q4 | $64.8M | Buy |
542,612
+28,586
| +6% | +$3.35M | 0.03% | 479 |
|
|
2022
Q3 | $54.6M | Buy |
514,026
+15,788
| +3% | +$1.6M | 0.03% | 515 |
|
|
2022
Q2 | $48.6M | Sell |
498,238
-17,330
| -3% | -$1.6M | 0.03% | 554 |
|
|
2022
Q1 | $48.3M | Buy |
515,568
+165,198
| +47% | +$14M | 0.02% | 619 |
|
|
2021
Q4 | $29.8M | Buy |
350,370
+76,040
| +28% | +$6.99M | 0.01% | 798 |
|
|
2021
Q3 | $26.3M | Buy |
274,330
+17,566
| +7% | +$1.66M | 0.01% | 803 |
|
|
2021
Q2 | $25M | Sell |
256,764
-168,462
| -40% | -$16.1M | 0.01% | 831 |
|
|
2021
Q1 | $41.4M | Sell |
425,226
-245,739
| -37% | -$25.8M | 0.02% | 670 |
|
|
2020
Q4 | $64.3M | Buy |
670,965
+102,801
| +18% | +$9.93M | 0.03% | 527 |
|
|
2020
Q3 | $54.6M | Buy |
568,164
+27,403
| +5% | +$3.17M | 0.03% | 493 |
|
|
2020
Q2 | $66M | Buy |
540,761
+61,881
| +13% | +$6.84M | 0.04% | 418 |
|
|
2020
Q1 | $41.4M | Sell |
478,880
-33,409
| -7% | -$3.27M | 0.03% | 505 |
|
|
2019
Q4 | $55.1M | Buy |
512,289
+103,841
| +25% | +$10.9M | 0.03% | 501 |
|
|
2019
Q3 | $36.8M | Sell |
408,448
-30,902
| -7% | -$2.89M | 0.02% | 602 |
|
|
2019
Q2 | $37.1M | Buy |
439,350
+28,628
| +7% | +$2.35M | 0.03% | 608 |
|
|
2019
Q1 | $36.2M | Buy |
410,722
+30,346
| +8% | +$2.54M | 0.03% | 581 |
|
|
2018
Q4 | $27.2M | Buy |
380,376
+216,131
| +132% | +$20.7M | 0.02% | 631 |
|
|
2018
Q3 | $20.2M | Sell |
164,245
-198,975
| -55% | -$22.6M | 0.02% | 750 |
|
|
2018
Q2 | $35.7M | Sell |
363,220
-16,719
| -4% | -$1.5M | 0.03% | 615 |
|
|
2018
Q1 | $31.5M | Sell |
379,939
-85,253
| -18% | -$7.2M | 0.02% | 646 |
|
|
2017
Q4 | $36.1M | Sell |
465,192
-54,520
| -10% | -$3.72M | 0.03% | 563 |
|
|
2017
Q3 | $31.8M | Buy |
519,712
+19,765
| +4% | +$1.04M | 0.03% | 584 |
|
|
2017
Q2 | $23M | Sell |
499,947
-95,311
| -16% | -$4.62M | 0.02% | 695 |
|
|
2017
Q1 | $25.8M | Buy |
595,258
+17,124
| +3% | +$734K | 0.03% | 624 |
|
|
2016
Q4 | $22.4M | Sell |
578,134
-21,489
| -4% | -$973K | 0.03% | 639 |
|
|
2016
Q3 | $30.4M | Sell |
599,623
-18,054
| -3% | -$899K | 0.03% | 528 |
|
|
2016
Q2 | $28.1M | Sell |
617,677
-10,583
| -2% | -$487K | 0.03% | 536 |
|
|
2016
Q1 | $24.8M | Buy |
628,260
+16,498
| +3% | +$655K | 0.03% | 572 |
|
|
2015
Q4 | $34.6M | Sell |
611,762
-2,297
| -0.4% | -$117K | 0.04% | 468 |
|
|
2015
Q3 | $24.4M | Sell |
614,059
-182,584
| -23% | -$8.82M | 0.03% | 613 |
|
|
2015
Q2 | $38M | Sell |
796,643
-93,355
| -10% | -$3.96M | 0.04% | 497 |
|
|
2015
Q1 | $35.3M | Sell |
889,998
-70,200
| -7% | -$2.51M | 0.03% | 522 |
|
|
2014
Q4 | $21.5M | Buy |
960,198
+30,800
| +3% | +$584K | 0.02% | 680 |
|
|
2014
Q3 | $14.6M | Buy |
929,398
+39,500
| +4% | +$590K | 0.01% | 752 |
|
|
2014
Q2 | $13.2M | Hold |
889,898
| – | – | 0.01% | 774 |
|
|
2014
Q1 | $14.3M | Buy |
889,898
+187,000
| +27% | +$3.2M | 0.02% | 745 |
|
|
2013
Q4 | $6.57M | Buy |
702,898
+221,500
| +46% | +$2.16M | 0.01% | 936 |
|
|
2013
Q3 | $5.45M | Buy |
481,398
+10,000
| +2% | +$137K | 0.01% | 965 |
|
|
2013
Q2 | $6.31M | Buy |
+471,398
| New | +$5.79M | 0.01% | 901 |
|
Other funds holding NBIX
UBS AM's NBIX Position: Q2 2026 in Review
UBS AM reduced its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2026, selling an estimated $10M and leaving 504,233 shares worth $85M. The position accounts for 0.02% of the portfolio, ranked #542.
UBS AM first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $174M in Q2 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- UBS AM held 504,233 shares of Neurocrine Biosciences worth $85M as of Q2 2026.
- UBS AM sold 67,486 Neurocrine Biosciences shares in Q2 2026, an estimated $10M.
- Neurocrine Biosciences made up 0.02% of UBS AM's portfolio in Q2 2026, its #542 holding.
- UBS AM first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Neurocrine Biosciences position peaked at $174M in Q2 2025.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.